SLCO1A2

Solute carrier organic anion transporter family member 1A2 · P46721 · SLCO1A2 on Sugi Atlas →

2,646 patent compounds predicted against SLCO1A2, 2,167 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
Rifamycin (SCHEMBL2320)	1.00	2/20
Rifampin (SCHEMBL23490)	1.00	2/20
Rifampin (SCHEMBL23491)	1.00	2/20
Rifampin (SCHEMBL23492)	1.00	2/20
Rifampin (SCHEMBL66289)	1.00	2/20
Rifamycin (SCHEMBL151824)	1.00	2/20
Rifamycin (SCHEMBL182452)	1.00	2/20
Rifampin (SCHEMBL1176203)	1.00	2/20
Rifampin (SCHEMBL13230041)	1.00	2/20
Rifampin (SCHEMBL14029509)	1.00	2/20
Rifampin (SCHEMBL14252040)	1.00	2/20
Rifampin (SCHEMBL14405975)	1.00	2/20
Rifampin (SCHEMBL5005944)	0.99	2/20
Rifampin (SCHEMBL5005948)	0.99	2/20
Rifampin (SCHEMBL3227161)	0.97	2/20
Rifampin (SCHEMBL3227173)	0.97	2/20
Rifampin (SCHEMBL1847302)	0.96	2/20
Rifampin (SCHEMBL4634484)	0.96	2/20
SCHEMBL13018210	0.94	2/20
SCHEMBL12232443	0.92	2/20

Clinical trials — most relevant to SLCO1A2 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Impact of Polymorphisms of OCT2 and OCTN1 on the Kinetic Disposition of Gabapentin in Patients Undergoing Chronic Use	PHASE4	COMPLETED
Genetic Basis for Variation in the Renal Elimination of Metformin	PHASE4	COMPLETED
Organic Cation Transporter 1 (OCT1), on Response to Metformin in Healthy Subjects	PHASE4	COMPLETED
The Interaction of Herbs and Statins	PHASE4	COMPLETED
Effect of Age on the Renal Clearance of Adefovir	PHASE4	WITHDRAWN
Drug Transporter Interaction Study PHENTRA_2015_KPUK	PHASE4	COMPLETED
A Study to Evaluate the Efficacy and Safety of AK3280 in Patients With Idiopathic Pulmonary Fibrosis	PHASE2	UNKNOWN
A Study Comparing CO-1.01 With Gemcitabine as First Line Therapy in Patients With Metastatic Pancreatic Adenocarcinoma (LEAP)	PHASE2	COMPLETED
Open Label Pharmacokinetic-Pharmacogenetic Study on Polymorphisms in the Organic Cation Transporter OCT1	PHASE1	COMPLETED
THE EFFECT OF CYP3A5 GENOTYPE ON THE PHARMACOKINETICS OF MARAVIROC	PHASE1	COMPLETED
Effect of, OAT3, on the Renal Secretion of Cefotaxime	PHASE1	COMPLETED
A Phase I First in Human Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of WGI-0301 in Patients With Advanced Solid Tumors	PHASE1	UNKNOWN
Statin Therapy to Improve Medication Adherence	PHASE1	COMPLETED
Identification and Validation of Biomarkers for Breast Cancer Resistance Protein (BCRP)	PHASE1	COMPLETED
PK Study of Oral and IV Clofarabine in High Risk Myelodysplasia+Acute Leukemias	PHASE1	COMPLETED
Genetic Variation in Organic Cation Transport 1 (OCT1) and Its Significance for Morphine Pharmacokinetics	PHASE1	COMPLETED
Pharmacokinetics (PK) Study of Once Daily Darunavir/Ritonavir and Twice and Once Daily Raltegravir in HIV-infected Subjects	PHASE1	COMPLETED
Pharmacokinetic Drug-Drug Interaction Study to Identify Biomarkers of Kidney Transporters	EARLY_PHASE1	COMPLETED
Gadoxetate Sodium Enhanced MRI as a Biomarker for Aggressive Prostate Cancer	EARLY_PHASE1	UNKNOWN
Immune Checkpoint Inhibitor (ICI)-Drug-Drug Interaction (DDI) Study	EARLY_PHASE1	NOT_YET_RECRUITING
Metformin Gastrointestinal Intolerance: Measurement of Mitochondrial Complex I	EARLY_PHASE1	COMPLETED
Impact of Polymorphisms of OAT1, OAT3, and OCT2 on Transportation of Potential Nephrotoxic Drugs	nan	COMPLETED
Cancer and Hearing Loss Related in Children	nan	COMPLETED
SLC13A5 Deficiency Natural History Study - United States Only	nan	ENROLLING_BY_INVITATION
SLC13A5 Deficiency Natural History Study - Remote Only	nan	ENROLLING_BY_INVITATION
Placental Transfer of Tenofovir	nan	COMPLETED
Renal and Hepatic Clearance Following High-Dose Methotrexate in Childhood ALL	nan	COMPLETED
Genetics of Hyperuricemia Therapy in Hmong	nan	COMPLETED
Impact of Genetics on Metformin Pharmacokinetics	nan	COMPLETED
Study of CYP2C19 and ALDH3A1 Polymorphisms in Breast Cancer Patients	nan	UNKNOWN

Related proteins — ESM-2 sequence neighbours (a SLCO1A2 binder may also engage these)

Protein	Name	Similarity
Q99J94	—	1.000	Q99J94 →
Q91YY5	—	1.000	Q91YY5 →
Q9EP96	—	1.000	Q9EP96 →
P70502	—	1.000	P70502 →
Q9QYE2	—	1.000	Q9QYE2 →
P46720	—	0.999	P46720 →
Q9QXZ6	—	0.999	Q9QXZ6 →
Q9QZX8	—	0.999	Q9QZX8 →
Q9JJL3	—	0.998	Q9JJL3 →
O88397	—	0.998	O88397 →
O35913	—	0.997	O35913 →
Q9NYB5	—	0.997	Q9NYB5 →
SLCO1B3	Solute carrier organic anion transporter family member 1B3	0.996	landscape →
Q9ERB5	—	0.993	Q9ERB5 →
G3V0H7	—	0.991	G3V0H7 →
Q9EPZ7	—	0.991	Q9EPZ7 →
SLCO1B1	Solute carrier organic anion transporter family member 1B1	0.989	landscape →
F5H094	—	0.989	F5H094 →
Q9UIG8	—	0.987	Q9UIG8 →
Q9GMU6	—	0.986	Q9GMU6 →
Q8R3L5	—	0.985	Q8R3L5 →
Q8HYW2	—	0.984	Q8HYW2 →
Q9VVH9	—	0.983	Q9VVH9 →
Q5RFF0	—	0.983	Q5RFF0 →
Q99N02	—	0.983	Q99N02 →
SLCO4C1	Solute carrier organic anion transporter family member 4C1	0.982	landscape →
Q86UG4	—	0.981	Q86UG4 →
Q8BGD4	—	0.980	Q8BGD4 →
Q71MB6	—	0.979	Q71MB6 →
Q66KG0	—	0.978	Q66KG0 →